The biological therapies targeting the inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukins (ILs)-12/23/17 have shown good efficacy, which have been the first-line systemic treatment for psoriasis in many national guidelines (Mahil et al., 2016; Amatore et al., 2019; Smith et al., 2020; Nast et al., 2021). The gene discussed is TNF; the disease is psoriasis.